Mechanisms that might be responsible for the low levels of high density lipoprotein (HDL) associated with hypertriglyceridemia were studied in an animal model. Specific monoclonal antibodies were infused into female cynomolgus monkeys to inhibit lipoprotein lipase (LPL), the rate-limiting enzyme for triglyceride catabolism. LPL inhibition produced marked and sustained hypertriglyceridemia, with plasma triglyceride levels of 633-1240 mg/dl. HDL protein and cholesterol and plasma apolipoprotein (apo) Al levels decreased; HDL triglyceride (TG) levels increased. The fractional catabolic rate of homologous monkey HDL apolipoproteins injected into LPL-inhibited animals (n = 7) was more than double that of normal animals (0.094±0.010 vs. 0.037±0.001 pools of HDL protein removed per hour, average±SEM). The fractional catabolic rate of low density lipoprotein apolipoprotein did not differ between the two groups of animals. Using HDL apolipoproteins labeled with tyramine-cellobiose, the tissues responsible for this increased HDL apolipoprotein catabolism were explored. A greater proportion of HDL apolipoprotein degradation occurred in the kidneys of hypertriglyceridemic than normal animals; the proportions in liver were the same in normal and LPL-inhibited monkeys.
Introduction
The inverse correlation between the levels of circulating high density lipoprotein (HDL) cholesterol and the incidence of coronary heart disease in Americans (1-3) emphasizes why it is important to completely understand the processes regulating the synthesis and catabolism of HDL. Production of circulat-ing HDL requires apolipoprotein (apo) synthesis by a number oftissues; lipoprotein secretion is followed by several processes in the circulation that alter the size and composition of the HDL particle. The major protein component of HDL, apo Al, is synthesized and secreted by the liver and intestine as a component of discoidal and small spherical particles (4) . These nascent HDL increase in size as they accept free cholesterol which is then converted to cholesteryl ester via the action of lecithin:cholesterol acyl transferase. Additional apolipopr'-teins (especially apo Cs and E) and lipid are transferred to HDL after hydrolysis of triglyceride (TG)' in the core of TGrich lipoproteins (chylomicrons and very low density lipoproteins [VLDL] ) by lipoprotein lipase (LPL) (4) . LPL is synthesized in a variety of tissues including adipose and muscle and its interaction with circulating lipoproteins is thought to occur while the enzyme is bound to the luminal side of capillary endothelial cells (5) .
HDL catabolism appears to occur via at least two pathways. The interaction of HDL with a specific lipoprotein receptor on the surface of cells, especially hepatocytes, may result in removal of some HDL from the circulation (6, 7) . Alternatively, after binding to its receptor, only lipid (but not protein) may be removed from the HDL particles. Studies in rats using HDL labeled in apo Al with radioiodinated tyramine-cellobiose (TC) and also labeled with [3H]cholesteryl ether (labels trapped after uptake by the cells) demonstrated that liver uptake of plasma HDL cholesteryl ether was greater than its uptake of apo Al (8) . By contrast, a greater amount of apo Al than HDL lipid was removed by the kidney. Injected apo Al was found in the proximal tubule of the kidney (9) . Therefore, some circulating HDL may be delipidated, perhaps via the actions of hepatic triglyceride lipase (HTGL) bound to hepatic capillary endothelium, and free apolipoprotein filtered and reabsorbed in the kidney. In some studies of human postheparin blood, the activity of HTGL was negatively correlated with levels of HDL cholesterol (10, I 1) and LPL activity was positively correlated with HDL levels (11, 12) . Because LPL and HTGL are located primarily on endothelial surfaces, their actions on lipoproteins resulting in these correlations probably occur in the circulation and affect HDL catabolic, rather than synthetic, events.
The studies reported here were designed to further delineate the relationship between LPL activity and circulating levels of HDL. The cynomolgus monkey has previously been used for studies of lipoprotein metabolism (13) (14) (15) and is a good model for human lipoprotein physiology. Infusion of anti-LPL antibodies into these monkeys has been reported to rapidly (within 3 h) cause increases in plasma and HDL TG, and decreases in total HDL mass (14) . We now report the effects of more prolonged LPL inhibition, and the resulting hypertriglyceridemia, on HDL apolipoprotein metabolism. In an effort to define the mechanism responsible for variations in HDL apolipoprotein fractional catabolic rate (FCR), the tissue sites of HDL protein degradation were determined and compared in normal and hypertriglyceridemic animals. These results demonstrate an important role for LPL activity in regulating rates of HDL apolipoprotein fractional catabolic rate and provide information about the mechanism responsible for the coordinate physiologic regulation of HDL and TG metabolism.
Methods
Animals. The protocols and procedures for these studies were reviewed and approved by the Columbia University Health Sciences Division Institutional Animal Care and Use Committee. Adult female cynomolgus monkeys weighing 3-4 kg were maintained on a low-fat laboratory diet (fat was -5% of weight and 10% of calories; Chow, Ralston Purina, St. Louis, MO). A total of 11 monkeys were used for these studies. Three animals each underwent two kinetic studies ofHDL and LDL protein, one without and one with infusion ofanti-LPL antibodies. The remaining studies were done in pairs so that a control and a LPL-inhibited animal each received the identical tracers. We have previously reported the effects ofinfusion of nonimmune globulins on lipoprotein levels and VLDL catabolism in this species (15) . The plasma cholesterol and TG levels in plasma and isolated lipoproteins were measured by enzymatic methods using an analyzer (ABA model 100 Autoanalyzer, Abbott Laboratories, Houston, TX), and HDL cholesterol was measured after precipitation of apo B-containing lipoproteins by addition of phosphotungstic acid-magnesium to plasma (16) .
3 d before insertion of intravenous catheters, monkeys were placed in a jacket-swivel apparatus (Alice King Chatham Medical Arts, Los Angeles, CA) to allow them to acclimate to this condition. The animals were fasted for 12-14 h before surgery and anesthetized with intramuscular ketamine (10 mg/kg body weight) and xylazine (2 mg) . Under sterile conditions the femoral vein was exposed and an intravenous catheter was inserted. The catheter was placed in a subcutaneous tunnel and exited from the back ofthe animal. The monkey was placed in the jacket; the catheter was threaded through a steel cable attached to the jacket and connected to a swivel on the top of the cage. This catheter was kept patent by infusion of normal saline (2-4 ml/h) and was used for infusion of antibodies and for chronic blood sampling. The animals were allowed I d to recover from this minor surgical procedure. They moved freely about the cage and appeared healthy and not distressed. Monkeys received a few drops of a saturated solution of potassium iodide in their drinking water for the week before each turnover study to prevent thyroidal uptake of radioactive iodine.
All blood samples were obtained from the femoral vein catheter. Before obtaining each blood sample , 1.5 ml of saline and 1.5 ml of blood were aspirated. Then, using a new 3-ml syringe which had been coated with a solution of EDTA (150 mg/ml) to prevent the blood from clotting, a blood sample (1.5 ml) was obtained. The initially removed blood and saline were then reinjected and the intravenous infusion restarted. Radioactive tracers were injected via an additional catheter, a 21 -gauge scalp vein needle inserted into the popliteal vein of the opposite side. After injection of the tracers and 3 ml of sterile saline, the scalp vein needle was removed. The amount ofblood taken from each animal was limited to 12 ml per 24 h and < 20 ml per study. This is < 10% of the animal's estimated blood volume. Owing to concerns regarding the effects of possible immunization of the monkeys with a foreign protein, no animal participated in more than one study that required injections of antibody.
Antibody preparation. Monoclonal anti-LPL IgG was prepared from ascites collected from mice which had received two intraperitoneal injections of 1 ml of 2,6,10,14-tetramethylpentadecane (pristane) (Sigma Chemical Co., St. Louis, MO) followed by an injection of 107 hybridoma cells that were producing antibodies against LPL (14) . The IgG was isolated by precipitation with (NH4)2SO4 followed by chromatography on diethyleaminoethyl Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ). The resulting monoclonal IgG (0.5-2 mg/ml of protein), as previously reported (14) , inhibits monkey LPL activity in vitro and in vivo and does not affect HTGL activity.
Antibody infusion. For studies of LPL inhibition the animals received intravenous injections of 4-8 mg of monoclonal IgG at the initiation of the study and additional injections containing an equal mass of IgG every 10-12 h. The amounts of IgG were chosen to contain sufficient specific IgG to inhibit more than twice the amount of LPL which would have been expected in monkey plasma after intravenous heparin administration. Kinetic studies were begun -12 h after LPL inhibition and the development of hypertriglyceridemia. Subsequent injections of IgG were given immediately after obtaining timed blood samples. (19) . The lipoproteins were separated from the free iodine by gel filtration over Sephadex G-50 (Sigma Chemical Co.), then mixed with 1 ml of monkey plasma and reisolated by ultracentrifugation. This step was performed to allow some of the exchangeable apolipoproteins (Cs and E) to transfer to VLDL and for the small amount of labeled albumin to exchange with unlabeled protein. The reisolated lipoproteins were then dialyzed against PBS. 5 ,uCi of each tracer was used for each study. HDL tracers were analyzed by polyacrylamide gel electrophoresis (PAGE) on 12.5% gels, the gels were sliced and radioactivity was determined. > 85% ofthe radioactivity migrated in a position corresponding to apo AI. For some studies, radiolabeled HDL was prepared using autologous labeled apo AI. Monkey apo Al was purified from delipidated HDL by gel filtration using a fast protein liquid chromatography system (FPLC, LCC 500, Pharmacia, Inc.) (20), radioiodinated using ICl, and incubated with monkey plasma (37°C for 18 h), and the labeled HDL were reisolated by ultracentrifugation.
Lipoprotein turnover studies. After intravenous injection of radioiodinated lipoproteins into the monkeys, blood samples were obtained at either 2 (25) . TC was kindly supplied by Dr. R. Pittman, University of California, San Diego. As described above, the labeled lipoproteins were mixed with monkey plasma and reisolated by ultracentrifugation before use. 2-5 gCi of labeled HDL was injected into a control and paired LPL-inhibited monkey. 24 h later the animals were killed by pentobarbital overdose. While the heart was still beating, catheters were inserted into the left ventricle and atrium and the animal was perfused with 3 liters of cold saline. Organs were obtained and the total radioactivity and percentage of trichloroacetic acid (TCA)-precipitable radioactivity in each organ were determined (25) . The percentage of tracer removed by each tissue was obtained by dividing the amount recovered in each organ by the amount of tracer initially injected. By using the initial and 24-h blood sample, the percentage of injected radioactivity remaining in the plasma was estimated. For comparison purposes, data were normalized for an injection of 5 utCi.
Effects ofLPL inhibition on plasma lipids. Injection of anti-LPL antibodies resulted in a rapid and sustained increase in circulating TG. As shown in Fig. 1 , by 20 h after the infusion of antibodies the plasma TG appeared to reach a new steady state. Table I lists the baseline TG, cholesterol, and HDL cholesterol levels for the animals studied and the maximum plasma TG level which was observed during LPL inhibition. The maximum TG level was somewhat variable from monkey to monkey and ranged from 633 to 1,240 mg/dl. It should be noted that the animals ate their usual low fat diet during the study. We anticipate that much higher levels of plasma TG, as is seen in human LPL deficiency, might have occurred with increased fat intake.
In several monkeys, plasma TG was monitored for several days after the completion of an LPL inhibition study. The passage of2-3 d was required, after discontinuing the antibody infusion, for the plasma TG level to return to baseline. The prolonged elevation of TG observed here probably reflects the time required for the clearance of the injected antibody (26) , rather than reflecting the resynthesis of LPL. (14) and is due to a decrease in both subclasses of HDL.
VLDL and HDL apoproteins, were assessed by PAGE of isolated lipoproteins in three separate studies and a representative gel is shown in Fig. 2 (28) have suggested that all plasma apo AI tracers may not be associated with HDL in hyperlipidemic monkeys. Thus, the reisolation of the tracer in the range of HDL before use verified that all the injected label was initially on HDL. When the distribution of radioactivity was assessed in the initial sample obtained after injection of the tracer into the monkeys, a slight increase in the amount of tracer found in the nonlipoprotein fraction ofplasma, d> 1.21 g/ml, was found in the LPL-inhibited monkeys. In the studies in which this was assessed (n = 5 pairs), after 24 h the percentage of the total plasma radioactivity in the nonlipoprotein fraction averaged 9.0±2.4% in the control monkeys and 14.0±3.4% in the LPLinhibited animals (mean±SEM, P = 0.08 by paired t test). In the LPL-inhibited plasmas, an insignificant increase in tracer recovered in lipoproteins of lower density than HDL was also noted, 12.4±2.4% vs. 9.6±1.2% (P= 0.34). As presented in Table IV , all three methods gave comparable FCRs for control HDL turnover studies. Moreover, unlike the data previously obtained by our laboratory for VLDL turnovers in cynomolgus monkeys (13, 15) , the FCR for HDL protein was relatively uniform among these Chow-fed monkeys. LPL ]apoB average HDL protein synthetic rate in control studies was 0.049±0.3 mg/h and in LPL-inhibited studies was 0.060±2.2 mg/h. These latter synthetic rates were not significantly different from each other (P = 0.65). Thus, apo Al synthetic rates were not decreased by inhibition of LPL. Such calculations do require some assumptions, especially when performed during such an acute intervention as LPL inhibition. For the studies using HDL protein tracers, they assume that the kinetic data and protein estimates represent apo Al; the tracer did, in fact, contain a small amount (< 15% of the total) of other labeled protein. In addition, they assume that the protein in reisolated HDL is the same as that ofthe tracer, mostly apo Al. As shown in Fig. 2, most Data for LDL kinetic studies in four control and four LPL-inhibited monkeys are given in Table IV and a representative study is shown in Fig. 3 (14) , we showed that LPL inhibition blocks LDL production by preventing the conversion of VLDL to LDL. The lack of effect of LPL inhibition on the fractional rate of LDL catabolism, furthermore, demonstrates that the changes in HDL FCR were specific and not due to a generalized effect associated with administration of the monoclonal antibody or associated with changes in plasma volume. In this regard, plasma volumes of the monkeys calculated from the distribution of injected tracer were not significantly different, 164±52 ml (average±SD) in control studies and 186±44 ml in LPL-inhibited studies.
Tissue uptake ofHDL. To determine whether labeled intact HDL, or HDL that had labeled apo Al exchanged onto the lipoprotein, should be used for studies oftissue uptake of HDL protein, an initial experiment was performed in which 13'I-TC-HDL and 251I-TC-apo Al HDL were simultaneously injected into a monkey. Fig. 4 shows the plasma decay curves for the two labels. The TC-apo Al was removed slightly more rapidly (FCRs of 0.026 for TC-apo Al vs. 0.038 pools per hour for TC-labeled whole HDL). Apo AI kinetic studies in humans performed using labeled apo Al have been compared to simultaneous studies in which labeled HDL was used. In one study, radioiodinated apo Al injected into humans was found to have a more rapid FCR than labeled apo AI on HDL (29) ; other investigators have, however, reported that identical results for human apo Al kinetics were obtained when either apo Al or HDL was used as the tracer (30, 31) . In our studies we did not We next tested whether major differences occurred in the distribution of labeled TC, injected as TC-HDL, between organs from control and LPL-inhibited monkeys. The amounts of radioactivity and the percentages of the injected dose in organs obtained from six monkeys (three control and three LPL-inhibited) after injection of '25I-TC-HDL are given in Tables V and VI. The major organs responsible for clearance of HDL apolipoprotein were the liver and kidney and significant amounts of label were also found in the spleen. Steroid producing glands (ovary and adrenal) are less important for HDL catabolism in the monkey than the rat (9) , which uses HDL as the major plasma source of cholesterol for steroidogenesis. In the control studies, the extraction of label per gram of tissue was slightly, 1.4-fold, greater for the kidney than the liver. Because of the larger size of the liver, per organ, the removal of tracer by the kidney was only 35% ofthe amount of tracer removed by the liver.
The three studies performed using paired control and experimental monkeys showed similar results; renal uptake of tracer was greater in LPL-inhibited monkeys and liver uptake was unchanged. The extraction of label per gram of tissue was -1.8-fold greater in kidneys of LPL inhibited monkeys and Radioactivity (average ± SEM) recovered in each organ was calculated by multiplying the uptake per gram by the total wet weight of each organ. To correct for variability in the amounts of tracer injected, data were normalized to an injection of S uCi. Studies were performed using paired animals and the data presented are the averages obtained from three control and three LPL-inhibited monkeys. The amount of tracer (average ± SEM) recovered in each organ was divided by the total injected dose. Percentage of dose remaining in plasma was determined by the difference between the amount of radioactivity in the initial (2-min) and final (24-h) blood samples. Studies were performed using paired animals and the data presented are the averages obtained from three control and three LPL-inhibited monkeys.
kidney clearance of label increased to 64% of that of liver. To best illustrate this difference in organ uptake with LPL inhibition, the ratio of the amount of label per gram wet weight of kidney versus gram wet weight of liver in each of the three pairs of animals are shown in Fig. 6 . Although there may have been some differences in the uptake by other organs, e.g., less uptake by the heart and more by the spleen during LPL inhibition, the percent difference in uptake of the injected tracer by those organs (Table VI) was too small to account for changes in plasma HDL protein FCR. The liver removed similar amounts of label in normal and LPL-inhibited monkeys. Thus, the increase in HDL protein FCR during LPL inhibition was, at least in part, due to increased removal of apoprotein by the kidney. At the conclusion of the study, less label remained in the plasma of the LPL-inhibited monkeys (22.5% vs. 39%, Table VI), consistent with the increased HDL protein FCR that occurred during LPL inhibition (see Table IV ). For reasons which are unclear, the total recovery of tracer in the organs from the LPL-inhibited monkeys was lower than that in the The studies were performed using three pairs of animals, monkeys 6-11, and the differences in the ratio between control and LPL-inhibited monkeys are significant (P < 0.05) by paired t test. control monkeys. It is possible that more tracer was eliminated in the urine or stool of these animals or that more label was taken up by tissues that were not sampled, such as bone marrow or brain. Even though the absolute uptake oftracer varied, the percents of non-TCA-precipitable counts, which represent TC associated with products ofthe intracellular degradation of its carrier protein, were identical in control and experimental monkeys, averaging 37% in the liver and 48% in the kidney. Both the lower amount of organ uptake and reduced amount of non-TCA-precipitable radioactivity compared to the rat studies (9) likely resulted from the shorter (24 vs . 48 h) duration of our studies.
Discussion
The risk of the development of coronary heart disease in humans is strongly related to the level of circulating HDL cholesterol (1-3 (44) showed that injection of Triton into rats resulted in more apo Al in the d > 1.21 g/ml fraction of plasma and increased fractional catabolism of this apoprotein. Free apo Al might also be generated during hydrolysis of TG-rich particles with apo Al on their surface.
An obvious question is whether alterations in HDL composition without concomitant changes in LPL activity, will lead to changes in HDL catabolism. As an initial approach to this question, iodinated normal and hypertriglyceridemic human HDL were injected into normolipidemic rats and monkeys. The turnover of these HDL were not different (data not shown). Remodeling of the lipid in the core ofthe injected lipoproteins should not have occurred in the studies in the rat, due to the lack ofcholesteryl ester transfer protein. The labeled apo Al might have, however, equilibrated with nonlabeled rat apo Al (45) . Such an equilibration would negate any differences in catabolism of the two HDL preparations. Hence, increased clearance of different HDL preparations appears to be difficult to demonstrate in vivo and will require other methods.
Although the hypertriglyceridemia produced in the monkeys was caused by immunological blockade of LPL, we contend that this is a reasonable model for many examples of hypertriglyceridemia and low HDL cholesterol levels in humans. Variations of LPL activity in humans are associated with changes in lipoproteins which are consistent with our findings in the monkey. This is best illustrated by the positive correlation between the activity of LPL and the rate of postprandial TG catabolism and HDL cholesterol levels (1 1, 46) . Thus, HDL cholesterol levels in general are an index of the activity of LPL in vivo.
Increases in apo Al FCR owing to abnormal HDL composition might occur in normolipidemic or hypertriglyceridemic humans who have low LPL activity. In some people with low levels of HDL, fasting hypertriglyceridemia is not present. Nontheless, these individuals may have elevated plasma TG levels much of the day when they are in a postprandial state. During hypertriglyceridemia the neutral lipid composition of HDL is altered by elevated levels of circulating TG as TG is exchanged for HDL cholesteryl ester (47, 48) . Thus, TG-rich HDL, comparable to that found in LPL-inhibited monkey plasma, may be formed. The increase in apo Al FCR and the low plasma apo Al levels in hypertriglyceridemic humans (33) may be due to mechanisms similar to those observed during LPL inhibition in our studies.
LPL inhibition and the ensuing hypertriglyceridemia did not appear to affect LDL FCR. Hypertriglyceridemic humans often have an increased LDL FCR (49, 50) and a metabolic defect that results in overproduction of VLDL and apoprotein B (the major structural protein of both VLDL and LDL) (51) (52) (53) . Despite the expanded pool of VLDL which may compete with LDL for binding to the LDL receptor (54) , LDL FCR is increased, suggesting that these patients may have a defect which increases LDL receptor activity in addition to or as a result of the regulatory defect in apo B production. In our studies LDL was isolated from normolipidemic monkeys and the same radioiodinated LDL preparations were injected into control and LPL inhibited monkeys. This protocol allowed us to evaluate specifically the way the host handled LDL rather than assessing differences which may be due to variations in LDL composition. LDL FCR was similar in both control and LPL-inhibited monkeys, suggesting that acute LPL inhibition did not alter processes, such as the activity of the LDL receptor, responsible for LDL catabolism. This interpretation requires several assumptions regarding the injection of control tracer LDL into LPL-inhibited monkeys. Very rapid exchange of cholesteryl esters occurs in monkeys (55, 56) . After injection, the tracer LDL may have been converted to LDL with a composition which closely resembled that of the autologus LDL. Thus, in the LPL-inhibited monkeys the LDL FCR may actually reflect the clearance of TG-rich LDL rather than normal LDL in these monkeys.
Our studies provide a model which suggests that variations in apo Al levels between humans due to variations in apo Al FCR may be a consequence of differences in LPL activity and rates of TG-rich lipoprotein lipolysis. In this regard, Magill et al. (57) reported that human apo Al FCR is inversely correlated with VLDL apo B FCR and adipose tissue LPL activity. Interventions that increase LPL activity, such as chronic exercise (58), insulin treatment of diabetes mellitus (59), or treatment with fibric acid derivatives (60), would be expected to (a) lower plasma TG, (b) increase plasma apo Al levels, and (c) increase HDL cholesterol levels. Variations in LPL activity may account for a significant portion ofthe variability in levels of HDL cholesterol and apolipoprotein and for mechanisms which affect atherogenic risk by alteration in HDL levels (61) .
